Table 2.
Adjusted mean change from baseline in total scores on various secondary efficacy outcome measures (LOCF), ITT Population
| Adjusted mean (SE) change from baseline | |||
|---|---|---|---|
|
Secondary outcome |
Placebo |
Desvenlafaxine 10 mg/d |
Desvenlafaxine 50 mg/d |
| MADRS total score |
–9.87 (0.63) |
–11.28 (0.63) |
–10.76 (0.63) |
| CGI-S total score |
–1.08 (0.07) |
–1.23 (0.07) |
–1.11 (0.07) |
| HAM-D6 total score |
–4.75 (0.27) |
–5.49 (0.27) |
–5.19 (0.27) |
| SDS total score |
–2.63 (0.48) |
–4.09 (0.48)† |
–3.78 (0.49) |
| SDS Work Studies component |
–0.61 (0.17) |
–1.10 (0.17)† |
–1.14 (0.17)† |
| SDS Social Life component |
–1.08 (0.18) |
–1.58 (0.17) † |
–1.36 (0.18) |
| SDS Life/Home Responsibilities |
–0.98 (0.17) |
–1.43 (0.17) |
–1.20 (0.17) |
| WHO-5 total score | 2.96 (0.36) | 4.51 (0.35)‡ | 3.73 (0.36) |
†p<0.05 and ‡p<0.01; ANCOVA model using treatment as factor and baseline as covariate.
CGI-S, Clinical Global Impressions–Severity; HAM-D6, 6-item Hamilton Rating Scale for Depression; ITT, intent to treat; LOCF, last observation carried forward; MADRS, Montgomery-Åsberg Rating Scale for Depression; SDS, Sheehan Disability Scale; WHO-5, World Health Organization 5-item Well-being Index.